The World Health Organization said it had concluded Wednesday to end preliminaries of hydroxychloroquine as a likely treatment for COVID-19 patients, discovering it didn't diminish the death rate.

Specialist Ana Maria Henao Restrepo, from the WHO's wellbeing crises program, told a virtual question and answer session in Geneva that the antimalarial sedate was being pulled back from its multi-nation Solidarity Trial of possible medicines.

"The inward proof from the Solidarity/Discovery Trial, the outside proof from the Recovery Trial and the joined proof from these enormous randomized preliminaries, united, recommend that hydroxychloroquine - when contrasted and the standard of care in the treatment of hospitalized COVID-19 patients - doesn't bring about the decrease of the mortality of those patients," she said.

"In view of this examination and on the audit of the distributed proof, the Executive Group of the Solidarity/Recovery Trial has met on two events and today we met with all the foremost specialists.

"After consideration, they have inferred that the hydroxychloroquine arm will be halted from the Solidarity Trial."

The declaration came two days after the United States pulled back crisis use authorizations for both hydroxychloroquine and chloroquine, two antimalarial drugs supported by President Donald Trump to treat the new coronavirus.